Literature DB >> 1520587

Classical oestrogen receptor is not detectable in pancreatic adenocarcinoma.

O M Taylor1, J Teasdale, P N Cowen, M J McMahon, E A Benson.   

Abstract

Recent reports have suggested the presence of oestrogen receptors (ER) in pancreatic carcinoma. Therefore the tumour may be sensitive to hormone manipulation therapy. We examined 23 biopsies of human pancreatic carcinoma tissue for the presence of ER. The tissue was assayed by two methods: Iso-electric focusing (IEF) and ER-ICA an immunocytochemical assay. All biopsies were tested with ER-ICA and ten by IEF. Each biopsy was assessed histologically for tumour content and 20 contained adenocarcinoma. None of the samples of pancreatic carcinoma were positive for ER using the ER-ICA, and none demonstrated the binding peak typical of ER in the IEF assay. These results suggest that in pancreatic carcinoma oestrogen receptor is either absent (or at very low levels), or of a different type to that found in breast and uterine tissue. On theoretical grounds at least, this must raise questions as to the oestrogen sensitivity of pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1520587      PMCID: PMC1977934          DOI: 10.1038/bjc.1992.303

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  31 in total

1.  Estrogen receptor protein of pancreas.

Authors:  A A Sandberg; R Y Kirdani; M J Varkarakis; G P Murphy
Journal:  Steroids       Date:  1973-08       Impact factor: 2.668

2.  Marked hyperlipidemia and pancreatitis associated with oral contraceptive therapy.

Authors:  F Davidoff; S Tishler; C Rosoff
Journal:  N Engl J Med       Date:  1973-09-13       Impact factor: 91.245

3.  Estrogen-induced pancreatitis in patients with previously covert familial type V hyperlipoproteinemia.

Authors:  C J Glueck; D Scheel; J Fishback; P Steiner
Journal:  Metabolism       Date:  1972-07       Impact factor: 8.694

4.  Antiestrogen therapy in pancreatic carcinoma: a preliminary report.

Authors:  K Tønnesen; M Kamp-Jensen
Journal:  Eur J Surg Oncol       Date:  1986-03       Impact factor: 4.424

5.  Oestrogen receptor proteins in malignant and fetal pancreas.

Authors:  B Greenway; M J Iqbal; P J Johnson; R Williams
Journal:  Br Med J (Clin Res Ed)       Date:  1981-09-19

6.  Analysis of binding of [3H]Estradiol to the cytosol fraction of rat pancreas: comparison with sites in the cytosol of uterus.

Authors:  A M Boctor; P Band; A Grossman
Journal:  Endocrinology       Date:  1983-08       Impact factor: 4.736

7.  Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors.

Authors:  K S McCarty; E Szabo; J L Flowers; E B Cox; G S Leight; L Miller; J Konrath; J T Soper; D A Budwit; W T Creasman
Journal:  Cancer Res       Date:  1986-08       Impact factor: 12.701

8.  Estrogen receptor immunocytochemical assay (ER-ICA): computerized image analysis system, immunoelectron microscopy, and comparisons with estradiol binding assays in 115 breast carcinomas.

Authors:  C Charpin; P M Martin; J Jacquemier; M N Lavaut; N Pourreau-Schneider; M Toga
Journal:  Cancer Res       Date:  1986-08       Impact factor: 12.701

9.  A comparison of two steroid receptor assays in breast cancer: dextran coated charcoal and isoelectric focusing.

Authors:  M Fernö; A Borg; A Norgren
Journal:  Anticancer Res       Date:  1983 Jul-Aug       Impact factor: 2.480

View more
  3 in total

1.  Cytosolic estrogen and progesterone receptors in exocrine pancreatic adenocarcinoma.

Authors:  C Mao; D Desaty; J M Howard
Journal:  Int J Pancreatol       Date:  1994-04

2.  Flutamide in unresectable pancreatic adenocarcinoma: a randomized, double-blind, placebo-controlled trial.

Authors:  Sanjay Singh Negi; Anil Agarwal; Adarsh Chaudhary
Journal:  Invest New Drugs       Date:  2006-05       Impact factor: 3.651

3.  Expression of estrogen receptors during growth of human pancreatic adenocarcinoma cells (Capan-1)-relationship with differentiation.

Authors:  E Hollande; M Fanjul; N Houti; J C Faye; P Courriere
Journal:  In Vitro Cell Dev Biol Anim       Date:  1998 Jul-Aug       Impact factor: 2.723

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.